ABVC BioPharma (NASDAQ:ABVC) Shares Down 7.6% – What’s Next?

ABVC BioPharma, Inc. (NASDAQ:ABVC)’s share price traded down 7.6% on Friday . The company traded as low as $1.29 and last traded at $1.33. 180,196 shares were traded during mid-day trading, an increase of 52% from the average session volume of 118,251 shares. The stock had previously closed at $1.44.

Analysts Set New Price Targets

Separately, Weiss Ratings downgraded shares of ABVC BioPharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 29th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has an average rating of “Sell”.

ABVC BioPharma Stock Performance

The company has a market cap of $34.58 million, a price-to-earnings ratio of -3.32 and a beta of 0.56. The business’s 50 day moving average price is $1.19 and its 200-day moving average price is $1.69.

ABVC BioPharma (NASDAQ:ABVC) last announced its quarterly earnings data on Monday, May 18th. The company reported ($0.06) earnings per share (EPS) for the quarter.

Hedge Funds Weigh In On ABVC BioPharma

A number of hedge funds have recently made changes to their positions in the business. Geode Capital Management LLC raised its stake in shares of ABVC BioPharma by 7.7% in the 4th quarter. Geode Capital Management LLC now owns 202,365 shares of the company’s stock valued at $431,000 after buying an additional 14,553 shares in the last quarter. Millennium Management LLC acquired a new position in shares of ABVC BioPharma in the 3rd quarter valued at $60,000. Finally, Citadel Advisors LLC acquired a new position in shares of ABVC BioPharma in the 3rd quarter valued at $48,000. Institutional investors and hedge funds own 11.38% of the company’s stock.

ABVC BioPharma Company Profile

ABVC BioPharma is a clinical-stage biotechnology company focused on the discovery and development of novel vaccine and immunotherapy candidates for oncology and infectious diseases. The company leverages a proprietary peptide-based platform to identify and synthesize immunogenic epitopes, aiming to stimulate targeted immune responses against tumor-associated and pathogen-derived antigens.

The company’s pipeline includes active immunotherapy programs designed to address a range of cancer indications, along with vaccine candidates targeting bacterial pathogens.